MDL 19301

Cat. No.:	HY-100286
CAS No.:	89388-38-5
Molecular Formula:	$C_{15}H_{21}NS_2$
Molecular Weight:	279.46
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MDL 19301 is a nonsteroidal, anti-inflammatory agent.
In Vivo	Oral administration of MDL 19301 inhibits rat paw edema induced by carrageenan (ED_{30}=4.8 mg/kg) or an Arthus reaction (ED_{30}=8.2 mg/kg p.o.). The oral dose which induces gastric ulceration in 50% of fasted rats is greater than 1,000 mg/kg, demonstrating a more favorable therapeutic ratio than conventional nonsteroidal anti‐inflammatory agents. The anti-inflammatory activity of MDL 19301, but not that of MDL 16,861, is attenuated by co-administration of an inhibitor of drug metabolite (SKF525A). This suggests that MDL 19301 is a prodrug of MDL 16,861 and this phenomenon would explain its lack of ulcerogenicity. Additional anti-inflammatory properties of MDL 19301 include inhibition of carrageenan pleurisy, adjuvant arthritis, and HOAc-induced writhing. Other pharmacological data indicate that MDL 19301 administration results in inhibition of prostaglandin synthesis; inhibition of arachidonic acid-induced, but not prostaglandin-E2-induced, diarrhea in mice; and inhibition of ex vivo arachidonic-acid-induced, but not ADP-induced, rat platelet aggregation. MDL 19301 and MDL 16,861 are unexpectedly weak antipyretic agents in rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. NS Doherty, et al. Pharmacological properties of MDL 19,301: A novel, nonsteroidal, anti-inflammatory agent. Drug Dev Res 1989 16(1) 31-44

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA